In the field of life sciences, Olink multiplex proteomics detection technology is gradually emerging, providing researchers and clinicians with unprecedented research perspectives and diagnostic/therapeutic approaches. This article delves into the principles of this technology, its core advantages, rich clinical application cases, technological breakthroughs, and future development directions, while also analyzing the challenges it faces and optimization strategies. Principles of Olink Multiplex Proteomics Olink multiplex proteomics detection relies on Proximity Extension Assay (PEA) technology. The ingenuity of this technique lies in using a pair of specific antibodies to recognize and bind the target protein, while separately labeling each antibody with a DNA oligonucleotide. When the antibody pair successfully binds the same protein, the DNA strands undergo complementary pairing and further extension, ultimately forming a DNA barcode that can be quantitatively detected. Combined with qPCR or high-throughput sequencing technology, precise quantitative analysis of proteins can be achieved. Core Advantages of This Technology 01 Ultra-high sensitivity: capable of detecting proteins at levels as low as fg/mL; this high sensitivity enables outstanding performance in the detection of complex body fluid samples such as plasma and serum, capturing trace yet critical protein information. 02 High throughput and flexibility: a single panel can cover 5 to 5400+ protein biomarkers; whether for targeted research or comprehensive whole-proteome exploration, it meets the diverse needs of researchers and clinicians, providing great convenience for research. 03 Multi-omics integration capability: can be organically combined with genomic, transcriptomic, and single-cell sequencing data to resolve disease mechanisms from multiple dimensions, offering a comprehensive perspective for in-depth understanding of disease onset and progression. Inflammatory Disease Subtyping and Mechanism Research 01 Inflammatory Bowel Disease (IBD): Researchers tested serum from 1,551 IBD patients, analyzing the expression of 86 inflammatory proteins. The results showed that proteins such as IL-17A and MMP-10 exhibited significant expression differences between Crohn's disease (CD) and ulcerative colitis (UC). Further analysis using machine learning models revealed the continuous disease-spectrum characteristics of IBD, providing a strong basis for clinically precise subtyping. 02 Acute and chronic pancreatitis: In a study of 231 samples, Th17-pathway-related proteins such as IL-17A and CCL20 showed specific upregulation in chronic pancreatitis. Meanwhile, macrophage activation signals continued to intensify as the disease progressed, laying an important foundation for identifying therapeutic targets. Tumor Immunotherapy and Patient Stratification 01 Bladder cancer: In a neoadjuvant therapy study, Olink detection revealed that elevated cytotoxic proteins such as TRAIL and FasL were closely associated with clinical complete response (cCR). This result helps formulate bladder-preservation treatment strategies, providing more personalized treatment options for bladder cancer patients. 02 Melanoma: Combined with single-cell transcriptomics, the study successfully elucidated the response mechanism to immune checkpoint inhibitors (ICB). By identifying 217 differentially expressed proteins, it enables more accurate guidance of patient stratification and medication optimization, improving therapeutic outcomes. Neuropsychiatric Disease Biomarker Discovery 01 Adolescent depression: The study identified 13 differentially expressed inflammatory proteins, including CCL4 and IL-18. Among them, TRAIL was negatively correlated with anxiety scores; a diagnostic model built by combining these biomarkers achieved an AUC of 0.819, providing a new perspective for deeply understanding the pathological mechanisms of depression. 02 Early prediction of dementia: Based on Olink 1536 proteomic data from UK Biobank, biomarkers such as GFAP and NEFL were screened out. These biomarkers can predict dementia risk 10 years before symptom onset (AUC > 0.87), making an important contribution to advancing the development of early dementia screening technologies. Skin Diseases and Immune Regulation 01 Atopic dermatitis (AD): Combined with single-cell transcriptomic analysis, the study revealed upregulation of dendritic cell–related proteins, further refining the immune regulatory network of the skin microenvironment and providing a new theoretical basis for the treatment of atopic dermatitis. Technological Breakthroughs and Future Outlook 01 High-throughput upgrade: Olink's newly launched Reveal platform supports the detection of 5400+ proteins; combined with NGS technology, sample requirements are further reduced to 1–6 μL of body fluid. This improvement makes the technology highly suitable for large-scale cohort studies such as UK Biobank, providing a powerful tool for large-scale disease research. 02 Accelerated clinical translation: From biomarker discovery to companion diagnostic development, Olink technology now covers the entire drug development chain. It shows tremendous potential especially in tumor immunotherapy and chronic disease management, promising more breakthroughs in clinical treatment. 03 Multi-omics integration: Deep integration with single-cell sequencing, spatial transcriptomics, and other technologies will drive precision medicine toward a "multi-dimensional, dynamic" direction, providing more comprehensive and accurate information for precise disease diagnosis and treatment. Challenges and Optimization Directions 01 Data standardization: Currently, detection standards across different studies have not been unified, which to some extent affects the comparability of cross-cohort results. Therefore, establishing unified data standards is one of the important issues to be addressed in the future. 02 Cost control: Although throughput has improved, the cost of high-density panels remains high, limiting the widespread application of the technology. How to reduce costs while ensuring technical performance is a challenge to be overcome. 03 Mechanistic validation: Functional studies of differential proteins should not rely solely on correlation analysis; they also need to be combined with in vitro experiments and animal models for in-depth validation, to avoid falling into the "correlation trap" and ensure the reliability of research results.
Olink Platform
